Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!
- – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World
The influence of physical activity in the progression of experimental lung cancer in mice
- PMID: 22683274
- DOI: 10.1016/j.prp.2012.04.006
GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
DMBA CARCINOGEN IN EXPERIMENTAL MODELS
Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto
Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.
Copyright © 2012 Elsevier GmbH. All rights reserved.Mestrado – ´´My´´ Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – Faculty of Medicine of Sao Jose do Rio Preto BaixarRedefine Statistical SignificanceBaixar
´´We propose to change the default P-value threshold for statistical significance from 0.05 to 0.005 for claims of new discoveries.´´ https://www.nature.com/articles/s41562-017-0189-z Published: Daniel J. Benjamin, James O. Berger, […]Valen E. Johnson Nature Human Behaviour volume 2, pages6–10 (2018)
´´My´´ Monograph – ´´Minha´´ Monografia – Induction of benznidazole resistance in human Trypanosoma cruzi isolates – Indução de resistência ao benzonidazol em isolados humanos de Trypanosoma cruzi – UFTM – Federal University of Triangulo Mineiro – Uberaba
Weird neutrino behavior could explain longstanding antimatter mystery @ CRISPR–Cas9 could allow ‘universal’ retinal cells for treating blindness – Researchers have found a way to enhance the production of retinal cells from ESCs, and also a method to allow them to remain undetected by the immune system. @ ‘We have a whole globe to protect’: Pandemic vaccine research speeds up @ CDC to launch clinical reporting app for COVID-19 in May @ SpaceX to launch NASA astronauts in historic mission – First privately owned and operated rocket to launch American astronauts – By James LeggateFOXBusiness @ Scientists in China have discovered more than 30 mutations of the new coronavirus, which they say may partly explain why it has been more deadly in certain parts of the world. @ FDA approves computer chip for humans – Devices could help doctors with stored medical information & Rapid development of an inactivated vaccine for SARS-CoV-2 @ Coronavirus: Scientists in China find 33 mutations of virus in warning to vaccine developers – Researchers say vaccine developers need to consider the impact of these “accumulating mutations… to avoid potential pitfalls” – David Mercer, news reporter David Mercer – News reporter @DavidMercerSky – Wednesday 22 April 2020 06:08, UK & Africa joins the race to trace COVID-19 with genomics @ Hundreds of People Volunteer to Be Infected with Coronavirus – Support grows for a controversial ‘human challenge’ vaccine study—but no trial is yet planned – By Ewen Callaway, Nature magazine on April 22, 2020 @ Virus Researchers Cast Doubt On Theory Of Coronavirus Lab Accident April 23, 20207:08 AM ET @ APRIL 21, 2020 More deaths, no benefit from malaria drug in VA virus study (Update) by Marilynn Marchione @ MIT community weighs in to address the coronavirus pandemic @ 04/25/2020 WBUR On Point: The Need For Innovation, Especially In A Crisis – The coronavirus pandemic has jump-started America’s innovation engine as companies, institutions and entrepreneurs step up to the challenge.
* Link about my monograph: Induction of benzonidazole resistance in human isolates of Trypanosoma cruzi: https://science1984.wordpress.com/2018/07/15/my-monography-chagas-disease-research-in-laboratory-2/
-Link about animal model diseases like cardiovascular diseases: https://science1984.wordpress.com/2020/04/29/33426/
– Links related with my dissertation: https://science1984.wordpress.com/2019/11/28/links-of-my-dissertation-the-influence-of-physical-activity-in-the-progression-of-experimental-lung-cancer-in-mice-and-monograph-induction-of-benzonidazole-resistance-in-human-isolates-of-trypanoso/
http://www.google.com http://www.yahoo.com http://www.gmail.com http://www.forbes.com http://www.harvard.edu http://www.princeton.edu http://www.mit.edu http://www.stanford.edu http://www.ucla.edu http://www.nobelprize.org http://www.nasa.gov
Liu, X., & Wang, X.-J. (2020). Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. BioRxiv, 2020.01.29.924100. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007236
Flav_R03 – USDA Database for the Flavonoid Content of Selected Foods
Novavax to Develop COVID-19 Vaccine with Initial $4M Budget from CEPI
The Coalition for Epidemic Preparedness Innovations (CEPI), a foundation that finances independent research projects for developing vaccines against emerging infectious diseases, awarded $4 million to Novavax, Inc. – a USA-based clinical-stage vaccine company that develops novel products for preventing a broad spectrum of infectious diseases – to accelerate the development of a COVID-19 vaccine based on its proprietary recombinant protein nanoparticle technology platform to be soon delivered to the Phase 1 clinical trial.
Novavax has produced and is currently assessing multiple recombinant nanoparticle vaccine candidates in animal models prior to advancing to clinical trials. Initiation of Phase1 clinical testing is expected in late spring of 2020. Novavax’ COVID-19 vaccine candidates were created with its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax also expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidates to enhance immune responses.
“The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines,” said Richard Hatchett, Chief Executive Officer of CEPI. “CEPI has moved quickly and urgently to coordinate with global health authorities and vaccine-development partners. CEPI is pleased to be partnering with Novavax to rapidly develop a potential vaccine candidate against the global threat posed by COVID-19.”
Novavax recently entered into an agreement with Emergent BioSolutions, Inc. (Emergent) to provide contract development and manufacturing services, supplying Novavax with vaccine product for preclinical testing and for use in its Phase 1 clinical trial. In addition, this arrangement offers the potential to leverage Emergent’s rapid deployment capabilities and expertise that provide Novavax scalability and capacity to produce vaccine product for future stockpiling. Emergent will utilize its two Baltimore, MD facilities to manufacture drug substance at its Bayview facility, designated by the U.S. Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), and drug product at its Camden facility.
Read the original article on GlobeNewswire.